2,479
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Influenza vaccine response: future perspectives

, , , &
Pages 1-5 | Received 18 Mar 2017, Accepted 10 Oct 2017, Published online: 19 Oct 2017

References

  • WHO. Influenza (seasonal). Fact sheet November 2016. Geneva (Switzerland): World Health Organization; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
  • Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36–44.
  • Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016;34:77–82.
  • US Food and Drug Administration. FDA information regarding FluMist quadrivalent vaccine. 2016 [cited 2016 Oct 3]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm508761.htm
  • Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65:1–54.
  • Tamura S, Ainai A, Suzuki T, et al. Intranasal inactivated influenza vaccines: a reasonable approach to improve the efficacy of influenza vaccine? Jpn J Infect Dis. 2016;69(3):165–179.
  • Buckland B, Boulanger R, Fino M, et al. Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine. 2014;32:5496–5502.
  • Du Y, Chen M, Yang J, et al. Molecular evolution and emergence of H5N6 avian influenza virus in central China. J Virol. 2017;91:e00143–17.
  • Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16:942–951.
  • Flannery B, Chung JR, Thaker SN, et al. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness – United States. Morb Mortal Wkly Rep. 2017;66:167–171.
  • Gomez Lorenzo MM, Fenton MJ. Immunobiology of influenza vaccines. Chest. 2013;143(2):502–510.
  • Buckland BC. The development and manufacture of influenza vaccines. Hum Vaccin Immunother. 2015;11(6):1357–1360.
  • Cox MM, Izikson R, Post P, et al. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines. 2015;3(4):97–108.
  • Suzuki Y, Odagiri T, Tashiro M, et al. Development of an influenza a master virus for generating high-growth reassortants for A/Anhui/1/2013(H7N9) vaccine production in qualified MDCK cells. PLoS One. 2016;11(7):e0160040.
  • Naito T, Mori K, Ushirogawa H, et al. Generation of a genetically stable high-fidelity influenza vaccine strain. J Virol. 2017;91:e01073–16.
  • Ren H, Zhou P. Epitope-focused vaccine design against influenza A and B viruses. Curr Opin Immunol. 2016;42:83–90.
  • Park MS, Kim JI, Park S, et al. Original antigenic sin response to RNA viruses and antiviral immunity. Immune Netw. 2016;16(5):261–270.
  • Bahadoran A, Lee SH, Wang SM, et al. Immune responses to influenza virus and its correlation to age and inherited factors. Front Microbiol. 2016;7:1841.
  • Khurana S, Frasca D, Blomberg B, et al. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog. 2012;8(9):e1002920.
  • Brodin P, Jojic V, Gao T, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015;160:37–47.
  • Saito N, Komori K, Suzuki M, et al. Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: a test-negative case-control study in Japan. Vaccine. 2017;35:687–693.
  • Trieu MC, Zhou F, Lartey S, et al. Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. J Infect Dis. 2017;215(5):740–749.
  • Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56:1363–1369.
  • Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58(3):319–327.
  • Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2015;211(10):1519–1528.
  • Martínez-Baz I, Casado I, Navascués A, et al. Effect of repeated vaccination with the same vaccine component against influenza A(H1N1)pdm09. J Infect Dis. 2017;215(6):847–855.
  • Yang LP. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults. Drugs. 2013;73(12):1357–1366.
  • De Vries RD, Altenburg AF, Rimmelzwaan GF. Universal influenza vaccines, science fiction or soon reality? Expert Rev Vaccines. 2015;14(10):1299–1301.
  • Nogales A, Martínez-Sobrido L. Reverse genetics approaches for the development of influenza vaccines. Int J Mol Sci. 2017;18(1):E20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.